Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| EyePoint, Inc.EYPT · Entity 5702 | Director | February 28, 2020 | March 03, 2020 |
| LISATA THERAPEUTICS, INC.LSTA · Entity 7814 | Director · President & CEO | January 09, 2026 | January 13, 2026 |
| PALISADE BIO, INC.SNCA · Entity 5803 | Director | April 01, 2021 | April 26, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
EyePoint, Inc.
Report date February 28, 2020 · Filed March 03, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 19,000 |
Reported balance
After 2020-02-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-02-28 · Grant · Acquired 19,000 · Balance 19,000 F1: Will fully vest on the one-year anniversary of the grant date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.29 · Expires 2030-02-28 | Direct | 33,500 |
Reported balance
After 2020-02-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-28 · Grant · Acquired 33,500 · Balance 33,500 |
Filing footnotes · ownership attribution and instrument terms
F1: Will fully vest on the one-year anniversary of the grant date.
LISATA THERAPEUTICS, INC.
Report date January 09, 2026 · Filed January 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 311,890 |
Last balance in matching sequence
After 2026-01-09 transaction · row 5
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
5 source rowsRow 1 · 2026-01-09 · Grant · Acquired 81,000 · Balance 352,986 F1: Represents 81,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2: Includes 124,750 unvested restricted stock. Row 2 · 2026-01-09 · Tax withholding · Disposed 10,503 · Balance 342,483 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 124,750 unvested restricted stock. Row 3 · 2026-01-09 · Tax withholding · Disposed 10,515 · Balance 331,968 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 124,750 unvested restricted stock. Row 4 · 2026-01-09 · Tax withholding · Disposed 12,224 · Balance 319,744 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 124,750 unvested restricted stock. Row 5 · 2026-01-09 · Tax withholding · Disposed 7,854 · Balance 311,890 F3: Shares withheld as payment of a tax liability on vesting of restricted stock. F2: Includes 124,750 unvested restricted stock. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2036-01-09 | Direct | 40,000 |
Reported balance
After 2026-01-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-01-09 · Grant · Acquired 40,000 · Balance 40,000 F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 81,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date.
F2: Includes 124,750 unvested restricted stock.
F3: Shares withheld as payment of a tax liability on vesting of restricted stock.
F4: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date.
PALISADE BIO, INC.
Report date April 01, 2021 · Filed April 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,000 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 6,000 · Balance 6,000 F1: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22.
F2: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 09, 2026 Filed Jan 13, 2026 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001334549-26-000003 · wk-form4_1768338591.xml · derivative · entry 6 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-09 F4 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 7,854 | $1.97 | $15,472.38 |
DisclosureSEC source: 0001334549-26-000003 · wk-form4_1768338591.xml · nonDerivative · entry 5 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 311,890 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 124,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 12,224 | $1.97 | $24,081.28 |
DisclosureSEC source: 0001334549-26-000003 · wk-form4_1768338591.xml · nonDerivative · entry 4 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 319,744 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 124,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 10,515 | $1.97 | $20,714.55 |
DisclosureSEC source: 0001334549-26-000003 · wk-form4_1768338591.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 331,968 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 124,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 10,503 | $1.97 | $20,690.91 |
DisclosureSEC source: 0001334549-26-000003 · wk-form4_1768338591.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 342,483 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 124,750 unvested restricted stock. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:09 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 81,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-26-000003 · wk-form4_1768338591.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 352,986 F1 · shares: Represents 81,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 124,750 unvested restricted stock. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 3,106 | $3.73 | $11,585.38 |
DisclosureSEC source: 0001334549-25-000002 · wk-form4_1736802514.xml · nonDerivative · entry 5 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,690 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 122,750 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001334549-25-000002 · wk-form4_1736802514.xml · derivative · entry 6 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-09 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 7,017 | $3.80 | $26,664.60 |
DisclosureSEC source: 0001334549-25-000002 · wk-form4_1736802514.xml · nonDerivative · entry 4 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 267,796 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 129,433 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 10,925 | $3.80 | $41,515.00 |
DisclosureSEC source: 0001334549-25-000002 · wk-form4_1736802514.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,813 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 129,433 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 9,414 | $3.80 | $35,773.20 |
DisclosureSEC source: 0001334549-25-000002 · wk-form4_1736802514.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,738 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 129,433 unvested restricted stock. Read SEC document |
| January 09, 2025 Filed Jan 13, 2025 21:08 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 81,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-25-000002 · wk-form4_1736802514.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,152 F1 · shares: Represents 81,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 129,433 unvested restricted stock. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 21:16 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 26,964 | $2.93 | $79,004.52 |
DisclosureSEC source: 0001334549-24-000006 · wk-form4_1727903753.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,834 F3 · shares: Shares withheld as payment of a tax liability on vesting of performance-based stock units. F2 · balance_after: Includes 107,183 unvested restricted stock. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 21:16 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 58,000 | $2.93 | $169,940.00 |
DisclosureSEC source: 0001334549-24-000006 · wk-form4_1727903753.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,798 F1 · shares: Reflects 58,000 in performance-based stock units, the criteria for which was satisfied on October 1, 2024 and which vested in full on that same day. F2 · balance_after: Includes 107,183 unvested restricted stock. Read SEC document |
| January 11, 2024 Filed Jan 12, 2024 21:02 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 1,026 | $2.99 | $3,067.74 |
DisclosureSEC source: 0001334549-24-000004 · wk-form4_1705093334.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 174,766 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 107,183 unvested restricted stock. Read SEC document |
| January 10, 2024 Filed Jan 11, 2024 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 3,470 | $3.00 | $10,410.00 |
DisclosureSEC source: 0001334549-24-000002 · wk-form4_1705007427.xml · nonDerivative · entry 4 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 175,792 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 109,166 unvested restricted stock. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 47,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001334549-24-000002 · wk-form4_1705007427.xml · derivative · entry 5 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2034-01-09 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 7,843 | $3.08 | $24,156.44 |
DisclosureSEC source: 0001334549-24-000002 · wk-form4_1705007427.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,262 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 115,850 unvested restricted stock. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 12,203 | $3.08 | $37,585.24 |
DisclosureSEC source: 0001334549-24-000002 · wk-form4_1705007427.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,105 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 115,850 unvested restricted stock. Read SEC document |
| January 09, 2024 Filed Jan 11, 2024 21:10 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 94,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-24-000002 · wk-form4_1705007427.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 199,308 F1 · shares: Represents 94,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 115,850 unvested restricted stock. Read SEC document |
| January 13, 2023 Filed Jan 17, 2023 22:05 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 397 | $3.65 | $1,449.05 |
DisclosureSEC source: 0001334549-23-000006 · wf-form4_167399310882456.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,543 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 60,350 unvested restricted stock. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:02 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 1,030 | $3.20 | $3,296.00 |
DisclosureSEC source: 0001334549-23-000004 · wf-form4_167355731008270.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,940 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 61,116 unvested restricted stock. Read SEC document |
| January 10, 2023 Filed Jan 11, 2023 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 3,470 | $3.20 | $11,086.65 |
DisclosureSEC source: 0001334549-23-000002 · wf-form4_167347112819363.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,970 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 63,100 unvested restricted stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.00 | $0.00 |
DisclosureSEC source: 0001334549-23-000002 · wf-form4_167347112819363.xml · derivative · entry 4 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-09 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | Tax withholdingCommon Stock | 7,845 | $3.00 | $23,535.00 |
DisclosureSEC source: 0001334549-23-000002 · wf-form4_167347112819363.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,440 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 69,783 unvested restricted stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 21:07 UTC | LISATA THERAPEUTICS, INC. LSTA · Entity 7814 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-23-000002 · wf-form4_167347112819363.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,285 F1 · shares: Represents 60,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 69,783 unvested restricted stock. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:03 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 69,742 | $0.50 | $34,871.00 |
DisclosureSEC source: 0001334549-22-000007 · wf-form4_166214899948261.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 739,444 F3 · shares: Shares withheld as payment of a tax liability on vesting of performance rights. F2 · balance_after: Includes 371,750 of unvested restricted stock. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 20:03 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 150,000 | $0.50 | $75,000.00 |
DisclosureSEC source: 0001334549-22-000007 · wf-form4_166214899948261.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 809,186 F1 · shares: Reflects 150,000 in performance rights, the criteria for which was satisfied on September 1, 2022 and which vested on that same date. F2 · balance_after: Includes 371,750 of unvested restricted stock. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 6,611 | $0.82 | $5,423.66 |
DisclosureSEC source: 0001334549-22-000004 · wf-form4_164253997450422.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 631,065 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F3 · balance_after: Includes 371,750 unvested restricted stock. Read SEC document |
| January 13, 2022 Filed Jan 18, 2022 21:06 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 6,471 | $0.81 | $5,217.57 |
DisclosureSEC source: 0001334549-22-000004 · wf-form4_164253997450422.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 637,676 F1 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 383,500 unvested restricted stock. Read SEC document |
| January 11, 2022 Filed Jan 12, 2022 21:21 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 16,740 | $0.87 | $14,481.77 |
DisclosureSEC source: 0001334549-22-000002 · wf-form4_164202250108559.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 644,147 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 395,000 unvested restricted stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:21 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.92 | $0.00 |
DisclosureSEC source: 0001334549-22-000002 · wf-form4_164202250108559.xml · derivative · entry 4 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-01-10 F5 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:21 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 56,410 | $0.92 | $51,727.97 |
DisclosureSEC source: 0001334549-22-000002 · wf-form4_164202250108559.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 660,887 F3 · shares: Shares withheld as payment of a tax liability on vesting of restricted stock. F2 · balance_after: Includes 424,750 unvested restricted stock. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 21:21 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 401,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-22-000002 · wf-form4_164202250108559.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 717,297 F1 · shares: Represents 401,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F2 · balance_after: Includes 424,750 unvested restricted stock. Read SEC document |
| April 01, 2021 Filed Apr 26, 2021 23:55 UTC | PALISADE BIO, INC. SNCA · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-21-002778 · ownership.xml · derivative · entry 1 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2 · security: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · shares: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. F1 · derivative.expiration_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2021 and ending March 31, 2022. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/21, 9/30/21, 12/31/21, and 3/31/22. Read SEC document |
| January 14, 2021 Filed Jan 15, 2021 21:02 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 5,936 | $1.56 | $9,260.16 |
DisclosureSEC source: 0001334549-21-000005 · wf-form4_161074450975521.xml · nonDerivative · entry 4 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,505 F2 · balance_after: Shares withheld as payment of a tax liability on vesting of restricted stock. F5 · balance_after: Includes 124,000 unvested restricted stock. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:02 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 6,425 | $1.55 | $9,958.75 |
DisclosureSEC source: 0001334549-21-000005 · wf-form4_161074450975521.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,441 F2 · balance_after: Shares withheld as payment of a tax liability on vesting of restricted stock. F4 · balance_after: Includes 135,750 unvested restricted stock. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:02 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 21,787 | $1.55 | $33,769.85 |
DisclosureSEC source: 0001334549-21-000005 · wf-form4_161074450975521.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,866 F2 · balance_after: Shares withheld as payment of a tax liability on vesting of restricted stock. F3 · balance_after: Includes 147,250 unvested restricted stock. Read SEC document |
| January 13, 2021 Filed Jan 15, 2021 21:02 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 39,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-21-000005 · wf-form4_161074450975521.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,653 F1 · balance_after: Reflects 39,000 in performance rights, the criteria for which was satisfied on January 13, 2021 and which vested on that same date. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:12 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001334549-21-000002 · wf-form4_161049314731155.xml · derivative · entry 4 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-01-11 F6 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:12 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 16,621 | $1.59 | $26,427.39 |
DisclosureSEC source: 0001334549-21-000002 · wf-form4_161049314731155.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,653 F2 · balance_after: Shares withheld as payment of a tax liability on vesting of restricted stock. F5 · balance_after: Includes 147,250 unvested restricted stock. Read SEC document |
| January 11, 2021 Filed Jan 12, 2021 23:12 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 119,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-21-000002 · wf-form4_161049314731155.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 311,274 F3 · shares: Represents 119,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. F4 · balance_after: Includes 177,000 unvested restricted stock. Read SEC document |
| January 08, 2021 Filed Jan 12, 2021 23:12 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 4,726 | $1.60 | $7,561.60 |
DisclosureSEC source: 0001334549-21-000002 · wf-form4_161049314731155.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,274 F1 · balance_after: Includes 58,000 unvested restricted stock. F2 · balance_after: Shares withheld as payment of a tax liability on vesting of restricted stock. Read SEC document |
| April 03, 2020 Filed Apr 7, 2020 21:29 UTC | PALISADE BIO, INC. SNCA · Entity 5803 | GrantRestricted Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-20-002462 · ownership.xml · derivative · entry 1 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Underlying: Common Stock · 6,000 shares Expires not disclosed F1 · security: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F2 · security: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · shares: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F2 · shares: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F1 · derivative.exercise_date: Represents partial compensation for services as a director of the Issuer for the board year commencing on April 1, 2020 and ending March 31, 2021. Provided the Reporting Person is a service provider to the Issuer at the time of vesting, the RSU's will vest in equal quarterly amounts on 6/30/20, 9/30/20, 12/31/20, and 3/31/21. F3 · derivative.expiration_date: N/A Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:57 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 33,500 | $0.00 Strike: $1.29 | $0.00 |
DisclosureSEC source: 0001562180-20-002054 · primarydocument.xml · derivative · entry 2 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,500 Underlying: Common Stock · 33,500 shares Expires 2030-02-28 Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:57 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantRestricted Stock Units · Derivative | 19,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-002054 · primarydocument.xml · derivative · entry 1 Mazzo David J · CIK 0001334549 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Common Stock · 19,000 shares Expires not disclosed F1 · derivative.expiration_date: Will fully vest on the one-year anniversary of the grant date. Read SEC document |
| January 14, 2020 Filed Jan 15, 2020 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 6,382 | $3.38 | $21,571.16 |
DisclosureSEC source: 0001334549-20-000005 · wf-form4_157912231463372.xml · nonDerivative · entry 3 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 186,382 F2 · balance_after: Includes 66,325 unvested restricted stock awards. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantStock Options (Right to Buy) · Derivative | 69,000 | $0.00 Strike: $3.28 | $0.00 |
DisclosureSEC source: 0001334549-20-000005 · wf-form4_157912231463372.xml · derivative · entry 4 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,000 Underlying: Common Stock · 69,000 shares Expires 2030-01-13 F3 · derivative.exercise_date: One-fourth of the shares underlying the stock options vest immediately on the grant date, with an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | Tax withholdingCommon Stock | 6,246 | $3.28 | $20,486.88 |
DisclosureSEC source: 0001334549-20-000005 · wf-form4_157912231463372.xml · nonDerivative · entry 2 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,764 Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 21:05 UTC | LISATA THERAPEUTICS, INC. CLBS · Entity 7814 | GrantCommon Stock | 46,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001334549-20-000005 · wf-form4_157912231463372.xml · nonDerivative · entry 1 Mazzo David J · CIK 0001334549 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,010 F1 · shares: Represents 46,000 restricted stock awards granted under the Issuer's 2018 Equity Incentive Compensation Plan. The restricted stock awards vest in four equal installments, with one-fourth of the shares vesting on the date of grant and an additional one-fourth vesting on each of the first, second and third annual anniversaries of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.